1. Home
  2. Companies
  3. EMV
  4. Material Events

Emvision Medical Devices (ASX:EMV) — Material Events

ASX:EMV · 21 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 15 articles Notable 6 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
EMVision Secures $12M Placement, Launches $2M Share Purchase Plan to Fuel GrowthMedium
EMVision raises $12M via placement, launches $2M Share Purchase Plan to fund clinical and commercial milestones
17 Sept 2025 ·Capital Raising ·85
EMVision Surpasses 200 Patients in emu™ Brain Scanner Trial, Eyes FDA MilestonesMedium
EMVision surpasses 200 patients in emu™ brain scanner pivotal trial, advancing FDA clearance pathway
31 Aug 2026 ·Clinical Trial Update ·85
EMVision Accelerates Stroke Tech Trials, Secures $15M in Funding BoostMedium
EMVision advances pivotal trial, secures $3M grant, raises $12M, and maintains strong cash position
28 Oct 2025 ·Appendix 4C Quarterly Activities & Cashflow Report ·85
EMVision Advances Brain Scanner Trials and Secures $17.1m Cash ReservesMedium
EMVision advances brain scanner trials, secures $17.1m cash, and expands clinical applications
15 July 2026 ·Quarterly Activities and Cashflow Report ·85
EMVision Expands emu™ Trial to Validate Acute Ischaemia DetectionMedium
EMVision expands emu™ trial to include acute ischaemia detection, boosting stroke diagnosis potential
11 May 2026 ·Clinical Trial Update ·85
EMVision Advances FDA Trial and Pre-Hospital Studies with $18.4m Cash ReserveMedium
EMVision advances FDA pivotal trial and pre-hospital studies with strong cash reserves and R&D funding
13 Apr 2026 ·Quarterly Activities and Cashflow Report ·80
EMVision Accelerates Stroke Scanner Trials with $17.5M Cash BackingMedium
EMVision advances clinical trials, secures funding, and maintains strong cash reserves
28 Jan 2026 ·Appendix 4C Quarterly Cashflow Report ·80
EMVision Advances Portable Brain Scanner Trials with 57% Revenue Growth and Reduced LossMedium
EMVision reports FY26 progress with increased revenue, reduced loss, and advances in brain scanner trials
24 Aug 2026 ·Annual Report ·80
EMVision Validates Brain Scanner for Aeromedical Stroke Care, Moves Closer to Commercial LaunchMedium
EMVision's Brain Scanner Proven Effective in Aeromedical Stroke Care Study, Advances Toward Commercial Production
27 May 2026 ·Clinical Study Results ·80
EMVision Boosts Funding with $3.8M R&D Rebate and Overseas ApprovalMedium
EMVision secures $3.8M R&D rebate and AusIndustry approval for overseas R&D tax rebate
16 Mar 2026 ·Corporate Update ·75
EMVision Accelerates emu™ Brain Scanner Trials with New US Hospital SitesMedium
EMVision advances emu™ Brain Scanner clinical trials with expanded hospital recruitment and new software features
27 Jan 2026 ·Clinical Trial Progress Update ·75
EMVision Launches Real-World Aeromedical Trial of Portable Stroke ScannerMedium
EMVision launches aeromedical study of First Responder brain scanner with Royal Flying Doctor Service
27 Nov 2025 ·Clinical Study Announcement ·75
EMVision Launches Rare Mobile Stroke Unit Study to Validate Brain ScannerMedium
EMVision launches Melbourne Mobile Stroke Unit study for First Responder Brain Scanner
24 Sept 2025 ·Clinical Study Announcement ·75
EMVision Unveils $2M Share Purchase Plan with Free Options at 16% DiscountMedium
EMVision launches $2M discounted Share Purchase Plan with free options, raising up to $12M including placements
29 Sept 2025 ·Capital Raising ·75
EMVision Raises $2M in Oversubscribed Share Plan, Boosting $14M Total for TrialsMedium
EMVision raises $2M via oversubscribed Share Purchase Plan, total $14M raised for clinical and commercial milestones
31 Oct 2025 ·Capital Raising ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.